中国处方药2024,Vol.22Issue(1) :83-86.

基于openFDA的曲妥珠单抗不良反应信号挖掘

ADR signal mining of trastuzumab based on openFDA

张晓沁 杨荣 李季丹
中国处方药2024,Vol.22Issue(1) :83-86.

基于openFDA的曲妥珠单抗不良反应信号挖掘

ADR signal mining of trastuzumab based on openFDA

张晓沁 1杨荣 1李季丹2
扫码查看

作者信息

  • 1. 南通市妇幼保健院药学部,江苏南通 226007
  • 2. 南通市妇幼保健院外科,江苏南通 226007
  • 折叠

摘要

目的 利用美国食品药品管理局数据库(OpenFDA)中的药品不良反应数据,挖掘曲妥珠单抗不良反应信号,为临床合理安全使用曲妥珠单抗提供参考.方法 统计和分析OpenFDA中 2004 年 1 月 1 日~2022 年 3 月 31 日上报的曲妥珠单抗不良反应报告;并使用报告比值比(ROR)法和比例报告比值比(PRR)法挖掘曲妥珠单抗不良反应信号.结果 曲妥珠单抗的不良反应报告共 52 545 例,女性为主(42 800 例,占 81.45%);年龄主要集中在 45~74 岁(24 004 例,占 43.78%);严重不良反应主要为住院治疗和死亡.分析后发现药品不良反应信号 37 个,说明书未记载的 4 个不良反应信号是头发生长异常、头发纹理异常、发色改变及脱水.结论 曲妥珠单抗说明书中记载的不良反应较为全面.但临床也应关注其对头发的不良反应和导致脱水的情况,并采取必要的防范措施.

Abstract

Objective To mining ADR signal of trastuzumab by using the drug adverse reactions database in OpenFDA,and to provide reference for the rational and safe use of trastuzumab in clinic.Methods The adverse reactions of trastuzumab reported by OpenFDA from January 1,2004 to March 31,2022 were counted and analyzed.The methods including reporting odd ratio(ROR),proportional reporting ratio(PRR)were used for mining of ADR signal related to trastuzumab.Results A total of 52 545 cases of trastuzumab adverse reactions were collected.The majority of patients were women(42 800 cases,81.45%).The age was mainly 45~74 years old(24 004 cases,43.78%).Serious adverse reactions were mainly hospitalization and death.After analysis,37 ADR signals were found.The four ADR signals not recorded in the instructions were hair growth disorder,hair texture abnormal,hair colour changes and dehydration.Conclusion The adverse reactions recorded in the instructions of trastuzumab are relatively comprehensive.However,clinical attention should also be paid to its adverse reactions to hair and the situation leading to dehydration,and necessary measures should be taken to prevent it.

关键词

曲妥珠单抗/药品不良反应/报告比值比法/比例报告比值比法/信号挖掘

Key words

Trastuzumab/Adverse drug reactions/Reporting odd ratio/Proportional reporting ratio/Signal mining

引用本文复制引用

出版年

2024
中国处方药
南方医药经济研究所

中国处方药

影响因子:0.649
ISSN:1671-945X
参考文献量7
段落导航相关论文